Drug Approval | July 02, 2022
Ascentage Pharma gets IND clearance by the US FDA for novel EED Inhibitor APG-5918
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
It is a two dose vaccine to be administered intramuscularly at 28 days apart
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Subscribe To Our Newsletter & Stay Updated
